NanoViricides, Inc. NNVC

NanoViricides announced that the Phase II trial of NV-387 for mpox has begun in the Democratic Republic of Congo with first patients enrolled. The adaptive, international, multi-center, randomized, open-label study (phase IIa/IIb) will compare NV-387 formulated as oral gummies to standard of care in mpox-infected patients and is registered in the Pan African Clinical Trials Registry (PACTR202609506749917). Principal Investigator Prof. Vivi Maketa Tevuzula (University of Kinshasa/IMABE) leads the trial; Om Sai Clinical Research Pvt. Ltd. from India is the CRO on site, with Lodja, Sankuru province as the trial site. MPox Clade I is endemic in DRC; there is no approved mpox drug. NV-387 is described as a host-mimetic, broad-spectrum antiviral with a low likelihood of viral escape, potentially offering Orphan Drug Designation (ODD) and readiness for SNS opportunities if approved. Phase II mpox trial initiation and potential designation opportunities could materially affect NNVC's pipeline value and market prospects.

NanoViricides plans clinical trial start next week for oral NV-387 to treat Ebola, aiming to cut fatalities and spread during expanding DR Congo outbreak with 48% fatality rate. Ebola trial initiation for NV-387 represents major product development step likely to boost company trajectory and sentiment.

NanoViricides registers clinical trial for its oral Ebola drug in the Pan African Clinical Trials Database. The trial is ready to start as the largest Ebola outbreak expands in DR Congo. Ebola drug trial registration advances NanoViricides core antiviral pipeline during active outbreak.

Measles cases rise in USA and globally. NanoViricides prepares clinical trials for broad-spectrum NV-387 as measles treatment. NV-387 trial preparations target rising measles cases with broad-spectrum antiviral but remain early-stage development step.

NanoViricides, Inc. will soon begin Phase II clinical trials of NV-387 oral gummies to treat Ebola in the Democratic Republic of Congo during the largest ever expanding outbreak. Phase II Ebola trial initiation in expanding outbreak marks major clinical and strategic progress for NanoViricides.

NanoViricides received regulatory approval for a Phase II clinical trial of NV-387 oral gummies to treat Ebola in DR Congo amid the largest expanding outbreak. Phase II approval for NV-387 enables potential market entry and revenue in major Ebola outbreak.

NanoViricides awaits approval from DR Congo regulatory agency for Phase II trial of NV-387 oral gummies to treat Ebola, with financing completed to support the study. Phase II Ebola trial approval and secured funding mark major advancement in development pipeline with potential to shift company trajectory.

Ebola deaths exceed 930 in two months. NanoViricides seeks DR Congo approval for Phase II trial of NV-387 oral gummies against Ebola. Trial application advances infectious disease program and may lift near-term sentiment without guaranteed approval or revenue.

NanoViricides gains National Ethics Committee approval for Phase II trial of NV-387 oral gummies as Ebola treatment in Congo while outbreak spreads to two more provinces. Phase II approval for NV-387 during active Ebola spread advances key antiviral program with direct regulatory and commercial relevance.

NanoViricides advances NV-387 oral gummies toward Phase II clinical trial for Ebola treatment in DR Congo as the epidemic spreads. Phase II trial progress for NV-387 during active Ebola outbreak signals major potential boost to valuation and market position.

Analyst projects 350% upside potential for NNVC stock tied to its experimental Ebola drug. Analyst projection of major upside on Ebola drug may lift short-term investor sentiment and share price.

US FDA granted Rare Pediatric Disease Drug designation to NV-387 for measles treatment, enabling NanoViricides to receive a Priority Review Voucher upon approval. Rare pediatric disease designation for NV-387 directly grants priority review voucher eligibility that can materially accelerate regulatory timelines and generate substantial non-dilutive value.

NanoViricides has shipped NV-387 oral gummies drug product to DR Congo for Phase II clinical trials. Shipment advances NV-387 into Phase II trials and represents measurable clinical development progress.

NanoViricides' NV-387 oral gummies proposal approved by Pillar Committee in DR Congo for Phase II Ebola trial as epidemic spreads. Phase II approval for NV-387 marks major product development progress for NanoViricides.

NanoViricides proposes Phase II trial of NV-387 oral gummies to treat rapidly growing Ebola outbreak, citing superior oral administration and antibody escape resistance. Phase II Ebola trial proposal during active outbreak signals major clinical and market advancement potential for NNVC.

NanoViricides states NV-387 is ready for immediate shipment to DRC amid Ebola emergency and compares favorably versus other treatment options. NV-387 shipment readiness for Ebola emergency use signals major product milestone with direct effects on company trajectory.

NanoViricides claims its broad-spectrum antiviral can tackle the Ebola strain behind the Congo outbreak. Positive claims on Ebola applicability may lift short-term sentiment and visibility for the antiviral pipeline.

NanoViricides positions NV-387 as a strong broad-spectrum drug candidate to address the Ebola global health emergency. NV-387 Ebola positioning may moderately lift NanoViricides visibility and development prospects.

NanoViricides, Inc. (NNVC) filed its quarterly report, highlighting advancement of NV-387 toward Phase II trials. NV-387 advancing to Phase II marks a major clinical milestone that could significantly boost investor sentiment and company trajectory.

Hantavirus outbreak in the US underscores urgent need for broad-spectrum antiviral drugs, highlighting NanoViricides, Inc. (NNVC)'s platform as a potential solution amid limited treatment options. Outbreak validates market demand for broad-spectrum antivirals, directly aligning with NNVC's drug development focus and likely boosting investor sentiment.

NanoViricides states its Phase I antiviral drug could address the antiviral treatment gap exposed by a hantavirus outbreak on a cruise ship. Positioning a Phase I antiviral drug against a timely hantavirus outbreak highlights competitive potential but limited by early development stage.

NanoViricides, Inc. (NNVC) secured FDA Orphan Drug Designation for NV-387, its investigational treatment for measles, granting benefits including seven years of market exclusivity upon approval, tax credits, and fee waivers to accelerate development. FDA Orphan Drug Designation for NV-387 provides NanoViricides regulatory incentives, market exclusivity, and validation of its antiviral platform, significantly advancing its pipeline and boosting investor sentiment.

FDA granted Orphan Drug Designation to NanoViricides' measles treatment, providing incentives like tax credits, fee waivers, and seven years of market exclusivity upon approval. Orphan Drug Designation validates the measles treatment candidate and unlocks regulatory incentives plus market exclusivity, significantly advancing NNVC's antiviral pipeline and investor appeal.

NanoViricides, Inc. (NNVC) antiviral drug NV-387 received FDA Orphan Drug Designation for measles treatment, granting benefits like market exclusivity, tax credits, and protocol assistance. FDA Orphan Drug Designation provides seven years of market exclusivity, development incentives, and regulatory advantages that significantly boost NNVC's pipeline value and investor sentiment.

US FDA grants Orphan Drug Designation to NanoViricides, Inc. (NNVC)'s NV-387 for measles treatment, providing benefits including seven-year market exclusivity, tax credits, and protocol assistance. Orphan Drug Designation validates NV-387's measles program and unlocks regulatory incentives like market exclusivity and funding support, significantly boosting NNVC's pipeline value and investor sentiment.

NanoViricides announces NV-387 could address surging global measles outbreaks amid rising cases. NV-387's potential application to escalating measles outbreaks represents a major strategic expansion into a pressing public health need, likely boosting investor sentiment and company trajectory.

NanoViricides seeks FDA rare pediatric disease designation for antiviral candidate NV-387. Rare pediatric disease designation enables a valuable priority review voucher that can generate substantial non-dilutive funding and accelerate NNVC's pipeline development.

NanoViricides, Inc. (NNVC) filed for Rare Pediatric Disease Designation for its measles drug, potentially qualifying for a priority review voucher if approved. Rare Pediatric Disease Designation filing positions NNVC for a valuable priority review voucher, enabling major funding and accelerating drug development trajectory.

NanoViricides, Inc. (NNVC) has submitted a request to the FDA for rare pediatric disease designation for its measles drug candidate NV-387, which could expedite development and provide a valuable priority review voucher upon approval. Pursuing rare pediatric disease designation for NV-387 positions NNVC for a lucrative priority review voucher upon approval, enhancing funding and accelerating measles drug development.

NanoViricides, Inc. (NNVC) filed an application for Rare Pediatric Disease Drug Designation for NV-387 to treat measles, with the resulting Priority Review Voucher (PRV) providing a strong business case. Rare Pediatric Disease Designation for NV-387 could yield a valuable Priority Review Voucher, enabling substantial non-dilutive funding and boosting NNVC's development pipeline and market valuation.